Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 9,115 matching trials from the live ClinicalTrials.gov search.
Filters: Tampa, Florida Clear all
Terminated Phase 2 Interventional Results available

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

NCT01586195
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 4 Interventional Results available

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

NCT00672139
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 1 Interventional Results available

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

NCT04128579
View directory record Official record
Conditions
Lupus Erythematosus, Lupus Nephritis
Interventions
Itolizumab [Bmab 600]
Drug
Lead sponsor
Biocon Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

NCT03924869
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
Radiation · Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 7:07 PM EDT
Recruiting Phase 2Phase 3 Interventional

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
CSL300, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
166
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Recruiting No phase listed Observational

Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)

NCT03999983
View directory record Official record
Conditions
Vertebral Artery Stenosis
Interventions
Observational Prospective Registry
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Jacksonville, Florida • Tampa, Florida • Winfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 31, 2026, 7:07 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

NCT05285553
View directory record Official record
Conditions
Myopia
Interventions
MiSight 1 Day, Proclear 1 day
Device
Lead sponsor
CooperVision, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
30
States / cities
Birmingham, Alabama • Fullerton, California • La Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

NCT07012031
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Not applicable Interventional Results available

Valor II: The Valiant Thoracic Stent Graft System Clinical Study

NCT00413231
View directory record Official record
Conditions
Thoracic Aortic Aneurysm
Interventions
Valiant Thoracic Stent Graft System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 31, 2026, 7:07 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

NCT02760602
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
98
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Not applicable Interventional Results available

Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence

NCT01090739
View directory record Official record
Conditions
Fecal Incontinence
Interventions
TOPAS Treatment for Fecal Incontinence
Device
Lead sponsor
ASTORA Women's Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
San Francisco, California • Tampa, Florida • Weston, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 31, 2026, 7:07 PM EDT
Active, not recruiting Phase 3 Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

NCT00673257
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
pharmacological study, dual x-ray absorptimetry
Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Walking Adaptability Post-Spinal Cord Injury

NCT01851629
View directory record Official record
Conditions
Incomplete Spinal Cord Injury, Brown Sequard Syndrome
Interventions
Locomotor Training, Cross-Sectional Testing (No Intervention)
Behavioral · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

NCT00569972
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 3 Interventional

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

NCT00135395
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir+ritonavir, Lopinavir+ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 31, 2026, 7:07 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

NCT02641639
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer
Interventions
Fosbretabulin tromethamine, Placebo
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 31, 2026, 7:07 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multicenter HomeVENT: Home Values and Experiences Navigation Track

NCT06102330
View directory record Official record
Conditions
Pediatric ALL, Respiratory Insufficiency, Communication
Interventions
HomeVENT decision support tool
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
4
States / cities
Tampa, Florida • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduction of Risk for Low Back Injury in Theater of Operations

NCT01401842
View directory record Official record
Conditions
Lower Back Injury
Interventions
Lumbar ext. high intensity progressive resistance exercise, Low intensity core stabilization exercise
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Tampa, Florida • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

NCT02361086
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, CRPC
Interventions
VT-464: given orally once daily in 28 day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 31, 2026, 7:07 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 31, 2026, 7:07 PM EDT